Top Markets
#1 Bedrock Bedrock +34.97%
#2 Naoris Protocol Naoris Protocol +26.67%
#3 IQ IQ +17.63%
#4 pippin pippin +17.29%
#5 Bitway Bitway +17.15%
#6 Irys Irys +15.35%
#7 peaq peaq +10.50%
#8 Chrema Coin Chrema Coin +10.12%
#9 XPLA XPLA +10.05%
#10 ETHGas ETHGas +8.06%
Coin of the day
Bedrock Bedrock
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #20441
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Share Price
$0.16328419
Market Cap
$204.14K
Change (1 day)
4.35%
Change (1 year)
102.45%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
Revenue for Fusion Antibodies plc (FAB)
Revenue in Sep 2025 TTM: $2.15M
According to Fusion Antibodies plc latest financial reports the company's current revenue (TTM) is $2.15M. In 2024 the company made a revenue of $1.43M a decrease compared to the revenue in the year 2023 that was $3.58M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Fusion Antibodies plc from 2013 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 2,257,473.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 560,997.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 668,407.67%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 423,215.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 255,843.08%
NL